Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate BHV-1510 in Advanced or Metastatic Epithelial Tumors
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 in Combination with Libtayo® to be Reported at ASCO
Dupixent® Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc.
Dupixent® sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
SAGA Metals Reports First Drill Hole at Trapper North Zone of Radar Property Intercepts Extensive Oxide
Homerun Resources Inc. Engages Minerali Industriali Engineering for Third Party Confirmation Testing and Reporting on the Santa Maria Eterna Silica Sand for the Manufacture of Antimony-Free Solar Glass as a Key Deliverable Under the Solar Plant Bankable Feasibility Study
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901
